Terms: = Sarcomas AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
763 results:
1. Mefenamic acid exhibits antitumor activity against osteosarcoma by impeding cell growth and prompting apoptosis in human osteosarcoma cells and xenograft mice model.
Ye J; Chang T; Zhang X; Wei D; Wang Y
Chem Biol Interact; 2024 Apr; 393():110931. PubMed ID: 38423378
[TBL] [Abstract] [Full Text] [Related]
2. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
[TBL] [Abstract] [Full Text] [Related]
3. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract] [Full Text] [Related]
4. Trifluoperazine activates AMPK / mtor / ULK1 signaling pathway to induce mitophagy in osteosarcoma cells.
Shen W; Zeng X; Zeng X; Hu B; Ren C; Lin Z; Zhang L; Rui G; Yasen M; Chen X
Chem Biol Interact; 2024 Apr; 392():110904. PubMed ID: 38360085
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological features of two ultra-rare cases of malignant perivascular epithelioid cell tumors (PEComas) involving the uterus with recent updates.
Rekhi B; Menon S
Indian J Pathol Microbiol; 2024; 67(1):137-140. PubMed ID: 38358203
[TBL] [Abstract] [Full Text] [Related]
6. Conjunctival leiomyosarcoma: A clinico-pathological study with in deep molecular characterization.
Santoro A; Angelico G; Mulè A; Minucci A; Giannuzzi F; Sammarco MG; Pagliara MM; Blasi MA
Pathol Res Pract; 2024 Mar; 255():155182. PubMed ID: 38335782
[TBL] [Abstract] [Full Text] [Related]
7. LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism.
Cai F; Liu L; Bo Y; Yan W; Tao X; Peng Y; Zhang Z; Liao Q; Yi Y
BMC Cancer; 2024 Feb; 24(1):166. PubMed ID: 38308235
[TBL] [Abstract] [Full Text] [Related]
8. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.
Kong Y; Li X; Zhang H; Fu B; Jiang HY; Yang HL; Dai J
Cell Death Dis; 2024 Jan; 15(1):57. PubMed ID: 38228583
[TBL] [Abstract] [Full Text] [Related]
9. Lnc-PSMA8-1 activated by GEFT promotes rhabdomyosarcoma progression via upregulation of mtor expression by sponging miR-144-3p.
Meng L; Shang H; Liu Q; Li Z; Wang X; Li Q; Li F; Zhao Z; Liu C
BMC Cancer; 2024 Jan; 24(1):79. PubMed ID: 38225540
[TBL] [Abstract] [Full Text] [Related]
10. Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Immunohistochemistry Can Be a Useful Ancillary Tool to Identify Perivascular Epithelioid Cell Tumor.
Wangsiricharoen S; Ingram DR; Morey RR; Wani K; Lazar AJ; Wang WL
Mod Pathol; 2024 Mar; 37(3):100426. PubMed ID: 38219952
[TBL] [Abstract] [Full Text] [Related]
11. Soy isoflavones induces mitophagy to inhibit the progression of osteosarcoma by blocking the AKT/mtor signaling pathway.
Zheng Z; Zhao X; Yuan B; Jiang S; Yan R; Dong X; Yao Q; Liang H
Mol Med; 2024 Jan; 30(1):5. PubMed ID: 38191316
[TBL] [Abstract] [Full Text] [Related]
12. Solute carrier family 35 member A2 regulates mitophagy through the PI3K/AKT/mtor axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.
Luo X; Zhang J; Guo C; Jiang N; Zhang F; Jiao Q; Xu K; Yang J; Qu G; Lv XB; Zhang Z
Gene; 2024 Mar; 898():148110. PubMed ID: 38151177
[TBL] [Abstract] [Full Text] [Related]
13. Phase I Study of mtorC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mtor/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
14. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
[TBL] [Abstract] [Full Text] [Related]
15. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
Mochizuki T; Ikegami M; Akiyama T
Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
[TBL] [Abstract] [Full Text] [Related]
16. SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).
Movva S; Matloob S; Handorf EA; Choy E; Merriam P; Flieder DB; Cai KQ; Zhou Y; Tetzlaff ED; Pagan C; Barker E; Veggeberg R; Zumpano D; Rink L; von Mehren M; George S
Clin Cancer Res; 2024 Jan; 30(2):315-322. PubMed ID: 37967116
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
18. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study.
Phadnis S; Wang X; Daw NC; Herzog CE; Subbiah IM; Zaky W; Gouda MA; Morani AC; Amini B; Harrison DJ; Piha-Paul SA; Meric-Bernstam F; Gorlick R; Schwartz CL; Subbiah V
ESMO Open; 2023 Dec; 8(6):101609. PubMed ID: 37879233
[TBL] [Abstract] [Full Text] [Related]
19. Epilepsy in gliomas: recent insights into risk factors and molecular pathways.
Rudà R; Bruno F; Pellerino A
Curr Opin Neurol; 2023 Dec; 36(6):557-563. PubMed ID: 37865836
[TBL] [Abstract] [Full Text] [Related]
20. Exploring the logic and conducting a comprehensive evaluation of AdipoRon-based adiponectin replacement therapy against hormone-related cancers-a systematic review.
Laurindo LF; Sosin AF; Lamas CB; de Alvares Goulart R; Dos Santos Haber JF; Detregiachi CRP; Barbalho SM
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2067-2082. PubMed ID: 37864589
[TBL] [Abstract] [Full Text] [Related]
[Next]
